Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates June 01, 2022 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022 May 09, 2022 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2022 Operating and Financial Results May 05, 2022 at 08:30 PM UTC
Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 April 26, 2022 at 08:10 PM UTC
Internal link ProQR to Participate in the Kempen Life Sciences Conference April 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy April 13, 2022 at 11:00 AM UTC
Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit April 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit March 23, 2022 at 08:30 PM UTC
Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board March 07, 2022 at 12:00 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results February 24, 2022 at 12:00 PM UTC
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 February 11, 2022 at 12:00 PM UTC
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen January 04, 2022 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 November 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference October 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals October 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals October 29, 2018 at 11:33 AM UTC
Internal link ProQR to Present at the Chardan Genetic Medicines Conference October 02, 2018 at 11:00 AM UTC